SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Discovery of New Small Molecule TLR4 Agonists for the Treatment of Allergic Rhinitis
Award last edited on: 12/14/2023

Sponsored Program
SBIR
Awarding Agency
NIH
Total Award Amount
$41,694
Award Phase
2
Solicitation Topic Code
NIAID
Principal Investigator
Juhienah Khalaf

Company Information

DiaCarta LLC

2600 Hilltop Drive Building B 3rd Floor
Richmond, CA 94806
   (800) 246-8878
   information@diacarta.com
   www.diacarta.com
Location: Single
Congr. District: 11
County: Contra Costa

Phase I

Contract Number: 272201800036C-P00001-9999-1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2019
Phase I Amount
$1
Direct to Phase II

Phase II

Contract Number: 75N91018C00036
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2019
Phase II Amount
$41,693
This pilot study is aimed at judging the efficacy of the lead compound with a clinically relevant allergenThe relevant allergen chosen for this study is the house dust mite Dermatophagoides pteronyssinus allergenDer pLoToxTM Natural Der pfrom Indoor Biotechnologies with a low endotoxin contentEUgWe are selecting this allergen because our team has extensive prior experience with this allergen in mouse studies and has previously determined the doses required for sensitization and challengesAlternativelywe could also use the timothy grass allergen Phleum pratense allergenLoToxTM Recombinant Phl pfrom Indoor Biotechnologiesas a more relevant allergen for allergic rhinitisbut this would require additional dose response studies to determine the amounts of allergen required for both sensitization and challenges in the murine systemWe propose to investigate the efficacy of one versus two treatments of lead compoundtwo different dosesin the Der pallergen model